APA (7th ed.) Citation

Shpitzer, D., Perry, C., Shragai, T., Melamed, G., Smith, M. R., Vitkon, R., . . . Avivi, I. (2026). Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations. Cancers, 18(9), 1471. https://doi.org/10.3390/cancers18091471

Chicago Style (17th ed.) Citation

Shpitzer, Dor, Chava Perry, Tamir Shragai, Guy Melamed, Mitchell R. Smith, Roy Vitkon, Hillel Alapi, and Irit Avivi. "Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab Vs. Obinutuzumab-Based Combinations." Cancers 18, no. 9 (2026): 1471. https://doi.org/10.3390/cancers18091471.

MLA (9th ed.) Citation

Shpitzer, Dor, et al. "Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab Vs. Obinutuzumab-Based Combinations." Cancers, vol. 18, no. 9, 2026, p. 1471, https://doi.org/10.3390/cancers18091471.